
Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and …
Jun 2, 2022 · We examined combined CDKN2A/MTAP deletion vs. CDKN2A deletion/mutation alone as predictors of poor ICI response. Methods: We curated clinical data for cancer patients (pts) treated with ICI at Dana-Farber Cancer Institute through 6/2021, who …
MTAP protein status is highly concordant with CDKN2A …
Our findings highlight CDKN2A HD and MTAP loss as prevalent genetic alterations in MIBC and mUC, particularly within the luminal‐URO subtype and FGFR3 ‐mutated, p53‐normal/wildtype tumours.
Enzyme-mediated depletion of methylthioadenosine restores T …
Sep 28, 2023 · Chromosomal region 9p21 containing tumor suppressors CDKN2A/B and methylthioadenosine phosphorylase (MTAP) is one of the most frequent genetic deletions in cancer. 9p21 loss is correlated with reduced tumor-infiltrating lymphocytes (TILs) and resistance to immune checkpoint inhibitor (ICI) therapy.
CDKN2A and MTAP Are Useful Biomarkers Detectable by Droplet …
Co-deletion of the CDKN2A and methylthioadenosine phosphorylase (MTAP) genes has been researched extensively and discovered to be a highly specific characteristic of MPM. Most studies have used FISH to detect the deletion of CDKN2A and IHC for MTAP as a surrogate for this.
MTAP immunohistochemistry is an accurate and reproducible
Jun 23, 2019 · MTAP immunohistochemistry is a reliable surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant mesothelioma. Interobserver agreement is excellent for interpretation of...
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer ... - PubMed
Feb 8, 2021 · The methylthioadenosine phosphorylase (MTAP) gene is located adjacent to the cyclin-dependent kinase inhibitor 2A (CDKN2A) tumor-suppressor gene and is co-deleted with CDKN2A in approximately 15% of all cancers.
Impact of CDKN2A/B, MTAP, and TERT Genetic Alterations on
Nov 15, 2022 · In IDHwt glioblastomas, CDKN2A, CDKN2B, and MTAP predict for poor prognosis. TERT and CDKN2A mutations are associated with worse survival only when treated with lower radiation doses, thus potentially providing a genetic marker that can inform clinicians on proper dose-fractionation schemes.
Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for …
Mar 27, 2025 · MTAP deletion occurs in 10–15% of all human cancers due to its proximity to the tumor suppressor gene CDKN2A. The loss of MTAP leads to accumulation of methylthioadenosine (MTA), which shares structural similarity to S-adenosyl methionine (SAM), the methyl donor for the cell-essential protein arginine methyltransferase 5 (PRMT5). By competing with SAM, MTA partially inhibits PRMT5, making ...
CDKN2A and MTAP Are Useful Biomarkers Detectable by Droplet …
Nov 13, 2020 · Co-deletion of the CDKN2A and methylthioadenosine phosphorylase (MTAP) genes has been researched extensively and discovered to be a highly specific characteristic of MPM. Most studies have used FISH to detect the deletion of CDKN2A and IHC for MTAP as a surrogate for this.
Deletions of CDKN2A and MTAP Detected by Copy-Number …
In this study, CDKN2A-MTAP co-deletion was associated with loss of both p16 and MTAP protein expression in all cases with homozygous deletion and in the majority of cases with heterozygous deletion of CDKN2A-MTAP.